Prevalence and associating factors of long COVID in pediatric patients during the Delta and the Omicron variants.
COVID-19
Delta variant
Omicron variant
SARS-CoV-2
long COVID
Journal
Frontiers in pediatrics
ISSN: 2296-2360
Titre abrégé: Front Pediatr
Pays: Switzerland
ID NLM: 101615492
Informations de publication
Date de publication:
2023
2023
Historique:
received:
19
12
2022
accepted:
09
05
2023
medline:
9
6
2023
pubmed:
9
6
2023
entrez:
9
6
2023
Statut:
epublish
Résumé
The number of pediatric COVID-19 infections is increasing; however, the data on long COVID conditions in children is still limited. Our study aimed to find the prevalence of long COVID in children during the Delta and Omicron waves, as well as associated factors. A single-center prospective cohort study was conducted. We included 802 RT-PCR-confirmed COVID-19 pediatric patients in the Delta and Omicron periods. Long COVID was defined as having symptoms for ≥3 months after infection. Parents and/or patients were interviewed by phone. Multivariable logistic regression was performed to find associated factors with long COVID. The overall prevalence of long COVID was 30.2%. The Delta period had more prevalence than the Omicron (36.3% vs. 23.9%). Common symptoms for patients 0-3 years' old were loss of appetite, rhinorrhea, and nasal congestion. Conversely, patients 3-18 years' old had hair loss, dyspnea on exertion, rhinorrhea, and nasal congestion. However, there was no significant negative impact on daily life. Most symptoms improved after a 6-month follow-up. Factors associated with long COVID-19 conditions were infection during the Omicron period (adjusted OR: 0.54; 95% CI: 0.39-0.74, Infection during the Omicron wave has a lower prevalence of long COVID. The prognosis is often favorable, and most symptoms gradually become less. However, pediatricians may schedule appointments to surveil long COVID in children with fever or rhinorrhea as an initial symptom.
Identifiants
pubmed: 37292374
doi: 10.3389/fped.2023.1127582
pmc: PMC10244785
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1127582Informations de copyright
© 2023 Lokanuwatsatien, Satdhabudha, Tangsathapornpong, Bunjoungmanee, Sinlapamongkolkul, Chaiyakulsil, Sritipsukho and Tantiyavarong.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
BMJ. 2022 Jan 14;376:o110
pubmed: 35031537
Eur J Pediatr. 2022 Apr;181(4):1597-1607
pubmed: 35000003
BMJ Med. 2023 Feb 1;2(1):e000385
pubmed: 36936268
Ital J Pediatr. 2021 Aug 26;47(1):177
pubmed: 34446085
Lancet Child Adolesc Health. 2021 Oct;5(10):708-718
pubmed: 34358472
Int J Infect Dis. 2020 Nov;100:327-332
pubmed: 32920235
BMJ. 2021 Sep 1;374:n2157
pubmed: 34470745
Sci Rep. 2022 Jun 23;12(1):9950
pubmed: 35739136
Mediterr J Hematol Infect Dis. 2022 May 01;14(1):e2022044
pubmed: 35615321
Cardiovasc Intervent Radiol. 2021 Aug;44(8):1286-1288
pubmed: 33884459
J Biomed Inform. 2009 Apr;42(2):377-81
pubmed: 18929686
Eur Respir J. 2022 Feb 3;59(2):
pubmed: 34210789
J Med Virol. 2020 Jul;92(7):747-754
pubmed: 32232980
Lancet Child Adolesc Health. 2021 Jun;5(6):e22-e23
pubmed: 33891880
Virol J. 2022 Sep 8;19(1):144
pubmed: 36076271
Acta Paediatr. 2023 Jun;112(6):1284-1286
pubmed: 36938946
New Sci. 2021 Feb 27;249(3323):10-11
pubmed: 33686318
BMJ. 2022 Jun 17;377:o1500
pubmed: 35714995
Acta Paediatr. 2021 Jul;110(7):2208-2211
pubmed: 33835507
J Biomed Inform. 2019 Jul;95:103208
pubmed: 31078660
EClinicalMedicine. 2022 Aug 27;53:101624
pubmed: 36051247